Immunotherapy For Recurrent, Metastatic or Persistent Cervical Carcinoma

What is an immuno-therapy?

Immuno-therapies are a relatively recent development that are sometimes used in the treatment of cancer. They may work by attacking the cancer cells directly, or by activating a patient’s own immune system to mount an effective attack against the cancer.


The TUMOR INFILTRATING LYMPHOCYTE (TIL) therapy being studied in this trial is an investigational immunotherapy named LN-145.

TIL are derived from a patient’s own immune cells called lymphocytes, and specifically T lymphocytes that can recognize and potentially kill the patient’s own cancer cells. Some of these cells naturally travel to, and penetrate existing cancerous tumors, and are then referred to as TUMOR INFILTRATING LYMPHOCYTES (TIL). However, for various reasons the immune-suppressive environment of the cancerous tumors limits their number and activity which diminishes their ability to effectively attack the cancer.

The TIL therapy under investigation in this clinical trial (LN-145) is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. After TIL are extracted from the tumor, they are multiplied in a laboratory until billions of TIL are obtained. Prior to receipt of TIL, patients receive a pre-conditioning therapy to reduce the immune suppressive environment of cancer that remains in the patient. The expanded TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. Patients receive up to 6 doses of interleukin 2 (IL-2) immediately following TIL infusion to support growth and activation of the TIL in the patient, and to augment the anti-cancer activity of the TIL therapy.


  1. Tumor is surgically isolated from patient.
  2. Tumor sample is shipped to the GMP facility where TIL are isolated and multiplied to generate billions of TIL over three weeks.
  3. Patient initiates a week of pre-conditioning therapy to prepare to receive TIL.
  4. TIL product is administered as a one-time therapy followed by up to 6 doses of IL-2 to support growth and activation of the TIL therapy inside the patient.

TIL Therapy has been Studied in Patients Since 1988


TIL therapy is based on an adoptive cell therapy regimen that was developed at the National Cancer Institute (NCI) and which is currently being applied at a small selection of leading cancer centers around the world. So far, most of the data on TIL therapy has been obtained from studies in metastatic melanoma, a form of aggressive skin cancer, as well as cervical cancer.

Recent data from two trials at the NCI in patients with metastatic melanoma confirmed TIL treatment was associated with high, durable objective responses. In a 93 patient Phase 2 trial, the objective response rate (ORR) was 56%.1  Another trial of 101 patients observed complete responses (CR, total elimination of detectable tumors) in 24% of patients, some of whom were free of disease for more than four years. 2

Data in cervical tumors has reported increased 5-year survival rates in patients with higher numbers of TILs.3 Additionally, autologous infusion of expanded TILs from cervical patients has documented partial and complete responses with durations greater than 22 months.4


C-145-04 is a Phase 2 clinical trial, enrolling patients with recurrent, metastatic or persistent cervical carcinoma which is not likely to be cured with surgery and/or radiation. Patients have received at least one prior treatment with systemic immunotherapy or chemotherapeutic treatment for cervical cancer.

The clinical trial is designed to determine if Iovance investigational TIL therapy (LN-145) is safe and effective for the treatment of recurrent, metastatic or persistent cervical carcinoma (helps patients live longer and/or slow down cancer progression).

There are several objectives to the trial, some of which aim to determine:

  • Whether LN-145 reduces or slows the progression of the cervical carcinoma.
  • Whether LN-145 eliminates all detectable cervical carcinoma.
  • Whether treatment with LN-145 extends the life of a patient without their cancer worsening.

LN-145 is an investigational therapy that is being tested in clinical studies and has not been approved by the FDA or any other agency for any indication. A clinical trial is designed to explore efficacy and safety of experimental therapies. You should talk to your doctor about the benefits and risks of participating in this trial.



  • You have been diagnosed with recurrent, metastatic or persistent cervical carcinoma
  • You have not received prior systemic treatment with the exception of chemoradiation or surgery for loco-regional disease, or
  • Your cancer progressed during or following prior systemic therapy, including therapy with or without pembrolizumab
  • You are at least 18 years old


If you satisfy these key eligibility criteria, you may be eligible to participate in this clinical trial.  There are other additional eligibility criteria that can only be assessed by a trial physician.

To talk with somebody and to learn more about the trial, please call: 1-866-565-4410

Further details for healthcare providers can be accessed below:

Trial Sites Currently Enrolling Patients

City State Institution
Phoenix Arizona St. Joseph’s Medical Center
Los Angeles California USC
La Jolla California UCSD
Miami Florida Sylvester Cancer Center
Tampa Florida Moffitt
Orlando Florida University of Florida
Augusta Georgia Augusta University
Chicago Illinois University of Chicago
Louisville Kentucky James Grahm Brown Cancer Center
New Orleans Louisiana LSU
Baltimore Maryland Johns Hopkins
Detroit Michigan Karmanos
Newark New Jersey Rutgers
Buffalo New York Roswell Park
Columbus Ohio Ohio State
Cleveland Ohio Cleveland Clinic
Pittsburgh Pennsylvania UPMC
Houston Texas MD Anderson
Milwaukee Wisconsin Medical College of Wisconsin
Pierre Bénite France Centre Hospitalier Lyon Sud
Lyon France Centre Léon Bérard
Villejuif Cedex France Gustave Roussy
Erlangen Germany Universitätsklinikum Erlangen
Dresden Germany Universitätsklinikum Carl Gustav Carus
Amsterdam Netherlands Academisch Medisch Centrum
Pamplona Spain Clínica Universidad de Navarra
Barcelona Spain Hospital Universitari Vall d’Hebrón
Barcelona Spain Institut Català d’Oncologia
Madrid Spain Hospital General Universitario Gregorio Marañon
Madrid Spain Hospital Universitario Madrid Sanchinarro
Bern Switzerland Inselspital
Lausanne Switzerland Centre Hospitalier Universitaire Vaudois Lausanne – Centre Pluridisciplinaire d’Oncologie
Bristol United Kingdom Bristol Haematology and Oncology Centre
London United Kingdom Sarah Cannon Research Institute London
London United Kingdom University College London Hospitals NHS Foundation Trust

1 Rosenberg, S.A., et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell TransferImmunotherapy. Clinical Cancer Research, 17(13), 4550-4557.

2 Goff, S.L., et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Journal of Clinical Oncology, 2016; 34(20), 2389-2397.

3 Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., and Wang, Y., 2011. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 8:59-66.

4 Stevanovic, S., Draper, L.M., Langhan, M.M., Campbell, T.E., Kwong, M.L., Wunderlich, J.R., Dudley, M.E., Yang, J.C., Sherry, R.M., Kammula, U.S., et al. 2015. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543-1550.